Eli Lilly (LLY) said Tuesday that it has launched 7.5 milligram and 10 milligram single-dose vials of Zepbound or Tirzepatide, priced at $499 per month through its self-pay Journey program.
The company also said it has lowered the prices of its 2.5 milligram and 5 milligram vials to $349 and $499 per month, respectively.
These new options are only available through "LillyDirect," Eli Lilly said, a system for direct pricing that removes third-party supply chain involvement.
Zepbound is also available in prefilled pens, with weekly maintenance doses of 5 milligrams, 10 milligrams, or 15 milligrams, the company said.
The company's shares were up 1.8% in recent Tuesday premarket activity.
Price: 896.51, Change: +15.11, Percent Change: +1.7
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。